V Takyar1, P Surana1, D E Kleiner2, K Wilkins3, J H Hoofnagle1, T J Liang1, T Heller1, C Koh1. 1. Liver Diseases Branch, National Institute of Diabetes & Digestive & Kidney Diseases, National Institutes of Health, Bethesda, MD, USA. 2. Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 3. Office of the Director, National Institute of Diabetes & Digestive & Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
Abstract
BACKGROUND: Serum fibrosis markers are useful in staging chronic hepatitis B (HBV) and C (HCV) virus but have not been evaluated in chronic hepatitis D virus (HDV). AIM: To evaluate the utility of serum fibrosis markers [fibrosis-4 score (FIB-4), aspartate aminotransferase (AST) to alanine aminotransferase (ALT) ratio, aspartate aminotransferase ratio (AAR), age-platelet index (API), AST-to-platelet-ratio-index (APRI) and Hui score] in HDV infection. METHODS: Clinical and histologic laboratory data from HBV, HCV and HDV patients were evaluated and serum fibrosis markers were calculated. The ability of fibrosis markers to detect advanced fibrosis (Ishak ≥4) and cirrhosis (Ishak = 6) were evaluated and compared between viral infections. RESULTS: A total of 1003 subjects (HCV = 701, HBV = 240 and HDV = 62) with mean age of 46 ± 11 and 66% male were evaluated. HDV subjects had higher ALT and AST than HCV and lower platelets than both HBV and HCV. Histologically, HDV had the greatest percentage of Ishak ≥4 and necroinflammation. FIB-4 performed best in detecting advanced fibrosis and cirrhosis in all viral cohorts. In HDV, area under the receiver operator curve (AUROC) 95% confidence intervals for detecting advanced fibrosis were: FIB-4 = 0.70 (0.55-0.84), API = 0.69 (0.55-0.82), APRI = 0.68 (0.54-0.82), Hui score = 0.63 (0.49-0.78), AAR = 0.63 (0.48-0.77). The AUROC for detecting cirrhosis in HDV were: FIB-4 = 0.83 (0.69-0.97), API = 0.80 (0.66-0.95), APRI = 0.75 (0.61-0.89), Hui score = 0.70 (0.49-0.91) and AAR = 0.70 (0.48-0.93). Adjustment of published cut-offs led to marginal improvements in FIB4 for advanced fibrosis and of APRI for cirrhosis in HDV. CONCLUSIONS: Serum fibrosis markers have lower performance accuracy in chronic HDV infected patients compared to HBV and HCV patients. Other noninvasive fibrosis markers should be explored to assist in the management of these patients. Published 2016. This article is a U.S. Government work and is in the public domain in the USA.
BACKGROUND: Serum fibrosis markers are useful in staging chronic hepatitis B (HBV) and C (HCV) virus but have not been evaluated in chronic hepatitis D virus (HDV). AIM: To evaluate the utility of serum fibrosis markers [fibrosis-4 score (FIB-4), aspartate aminotransferase (AST) to alanine aminotransferase (ALT) ratio, aspartate aminotransferase ratio (AAR), age-platelet index (API), AST-to-platelet-ratio-index (APRI) and Hui score] in HDV infection. METHODS: Clinical and histologic laboratory data from HBV, HCV and HDVpatients were evaluated and serum fibrosis markers were calculated. The ability of fibrosis markers to detect advanced fibrosis (Ishak ≥4) and cirrhosis (Ishak = 6) were evaluated and compared between viral infections. RESULTS: A total of 1003 subjects (HCV = 701, HBV = 240 and HDV = 62) with mean age of 46 ± 11 and 66% male were evaluated. HDV subjects had higher ALT and AST than HCV and lower platelets than both HBV and HCV. Histologically, HDV had the greatest percentage of Ishak ≥4 and necroinflammation. FIB-4 performed best in detecting advanced fibrosis and cirrhosis in all viral cohorts. In HDV, area under the receiver operator curve (AUROC) 95% confidence intervals for detecting advanced fibrosis were: FIB-4 = 0.70 (0.55-0.84), API = 0.69 (0.55-0.82), APRI = 0.68 (0.54-0.82), Hui score = 0.63 (0.49-0.78), AAR = 0.63 (0.48-0.77). The AUROC for detecting cirrhosis in HDV were: FIB-4 = 0.83 (0.69-0.97), API = 0.80 (0.66-0.95), APRI = 0.75 (0.61-0.89), Hui score = 0.70 (0.49-0.91) and AAR = 0.70 (0.48-0.93). Adjustment of published cut-offs led to marginal improvements in FIB4 for advanced fibrosis and of APRI for cirrhosis in HDV. CONCLUSIONS: Serum fibrosis markers have lower performance accuracy in chronic HDV infectedpatients compared to HBV and HCV patients. Other noninvasive fibrosis markers should be explored to assist in the management of these patients. Published 2016. This article is a U.S. Government work and is in the public domain in the USA.
Authors: Elliot B Tapper; Eric B Cohen; Keyur Patel; Bruce Bacon; Stuart Gordon; Eric Lawitz; David Nelson; Imad A Nasser; Tracy Challies; Nezam Afdhal Journal: Clin Gastroenterol Hepatol Date: 2012-01-28 Impact factor: 11.382
Authors: Wornei Silva Miranda Braga; Cintia Mara Costa de Oliveira; José Ribamar de Araújo; Marcia da Costa Castilho; Joelma Martins Rocha; Joao Bosco de Lima Gimaque; Maria Luana Cristiny Rodrigues Silva; Heline Lira Vasconcelos; Rajendranath Ramasawmy; Raymundo Paraná Journal: J Hepatol Date: 2014-06-04 Impact factor: 25.083
Authors: B Nalpas; A Vassault; A Le Guillou; B Lesgourgues; N Ferry; B Lacour; P Berthelot Journal: Hepatology Date: 1984 Sep-Oct Impact factor: 17.425
Authors: Christopher Koh; Laetitia Canini; Harel Dahari; Xiongce Zhao; Susan L Uprichard; Vanessa Haynes-Williams; Mark A Winters; Gitanjali Subramanya; Stewart L Cooper; Peter Pinto; Erin F Wolff; Rachel Bishop; Ma Ai Thanda Han; Scott J Cotler; David E Kleiner; Onur Keskin; Ramazan Idilman; Cihan Yurdaydin; Jeffrey S Glenn; Theo Heller Journal: Lancet Infect Dis Date: 2015-07-16 Impact factor: 25.071
Authors: K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween Journal: J Hepatol Date: 1995-06 Impact factor: 25.083
Authors: Leon A Adams; Max Bulsara; Enrico Rossi; Bastiaan DeBoer; David Speers; Jacob George; James Kench; Geoffrey Farrell; Geoffrey W McCaughan; Gary P Jeffrey Journal: Clin Chem Date: 2005-07-28 Impact factor: 8.327
Authors: Pavel Bogomolov; Alexander Alexandrov; Natalia Voronkova; Maria Macievich; Ksenia Kokina; Maria Petrachenkova; Thorsten Lehr; Florian A Lempp; Heiner Wedemeyer; Mathias Haag; Matthias Schwab; Walter E Haefeli; Antje Blank; Stephan Urban Journal: J Hepatol Date: 2016-04-27 Impact factor: 25.083
Authors: Raffaella Romeo; Barbara Foglieni; Giovanni Casazza; Marta Spreafico; Massimo Colombo; Daniele Prati Journal: PLoS One Date: 2014-03-21 Impact factor: 3.240
Authors: Ben L Da; Pallavi Surana; Varun Takyar; David E Kleiner; Theo Heller; Christopher Koh Journal: J Viral Hepat Date: 2019-12-09 Impact factor: 3.517
Authors: Mariana Pinheiro Alves Vasconcelos; Deusilene Vieira DallÁcqua; Heiner Wedemeyer; Steven S Witkin; Maria Cássia Mendes-Corrêa; Juan Miguel Villalobos-Salcedo Journal: Am J Trop Med Hyg Date: 2020-05-14 Impact factor: 2.345
Authors: María B Pisano; Cecilia G Giadans; Diego M Flichman; Viviana E Ré; María V Preciado; Pamela Valva Journal: World J Gastroenterol Date: 2021-07-14 Impact factor: 5.742